What makes real world outcomes in soft @entity242 ? A mono-institutional XXXX experience.

@entity1 @entity4350 @entity137 @entity242 @entity1398
INTRODUCTION: @entity4350 proved its efficacy in relapsed @entity242 (STS) in 3 multicenter phase II studies with selected @entity1 . The aim of the present study is to investigate @entity4350 efficacy and tolerance in a cohort of "real-life" unselected @entity1 with @entity242 . METHODS: A single-center analysis was carried out on all consecutive @entity1 with histologically proven unresectable advanced or metastatic STS, who received at least one cycle of @entity4350 . Data on efficacy and tolerance were retrospectively reported. RESULTS: From 2004 to 2014, data of 59 @entity1 were reviewed. Median age was 62 years (from 23 to 87). A total of 317 cycles of @entity4350 were administered. Twenty-five @entity1 (42%) suffered grade 3-4 hematological @entity137 , mainly with @entity1398 (22 @entity1 , 37%). Disease control rate was 24%, mainly with stable disease, and 45 @entity1 (76%) experienced disease progression. Median overall survival was 6.6 months (95%CI [4.9-12.6]). CONCLUSION: @entity4350 might be an option for @entity1 without any other validated alternative, but phase III study evaluating @entity4350 +best supportive care (BSC) versus BSC is necessary.
